Charles River Laboratories International news

Named among leading companies in a growing market driven by stricter regulatory requirements, drug complexity, and outsourcing trends favoring specialized service providers.

While maintaining Zacks Rank #2 (Buy) with positive earnings outlook, higher forward P/E (24.87), higher PEG ratio (2.76), and weaker Value grade (D) suggest less attractive valuation relative to Progyny.

Mixed signals: positive near-term stock performance (+10.5%) and raised 2026 guidance, but offset by declining revenues (-2.7%), downward estimate revisions post-earnings, weak Growth (D) and Momentum (F) scores, and overall VGM Score of F. The Zacks Rank #2 (Buy) suggests potential, but fundamental weakness and negative estimate trends indicate caution.

Featured as a major company in the growing animal testing and non-animal alternative testing market, positioned to benefit from market expansion projected to reach $23.01 billion by 2035.

Mentioned as a former employer of course instructor Donna Taylor where she gained experience in monitoring veterinary clinical trials. No direct business impact or strategic information provided.

Despite divesting $287 million in combined revenue, the company raised its 2026 adjusted earnings guidance and expects significant margin improvement (100+ basis points) and EPS accretion (~10 cents), indicating a strategic restructuring that improves profitability and operational efficiency.

Featured as a major player in the rare disease CRO market, benefiting from rising R&D spending and demand for specialized clinical trial management services.

Stock returned 21.1% following upgrade to Zacks Rank #2 on July 14

Listed as a key market participant but without specific emphasis on positioning advantages relative to other competitors in the pathology services market.

Mentioned as the largest holding in RSPH (2.28% of assets) with no performance commentary, serving only as a factual disclosure of fund composition.

Key competitor in the expanding large molecule bioanalytical testing market, benefiting from growing demand for specialized testing services and outsourcing trends.

Featured as a prominent market participant in a growing clinical trials sector benefiting from increased pharmaceutical R&D investment and outsourcing trends.

Identified as a key player in the cell and gene therapy CDMO market with established manufacturing and testing capabilities, well-positioned for market growth.

Listed as a major company in the rapidly growing cell banking outsourcing market with 16.71% CAGR through 2031, indicating strong market tailwinds and expansion opportunities for established service providers.

Identified as a leading plasmid DNA manufacturing company with subsidiary Cobra Biologics also mentioned, positioning the company to benefit from market growth.

Key CDMO player in the AAV manufacturing market, benefiting from outsourcing trends and rising demand for contract manufacturing services.

Listed among leading companies in drug development services, well-positioned to benefit from increased R&D investments and demand for preclinical and clinical research services.

Listed as a key player in the expanding pharmaceutical microbiology QC testing market, which benefits from regulatory requirements and increased outsourcing of testing services.